Semaglutide Regulatory Status in Canada Health Canada Approval Status (Ozempic, Wegovy, Rybelsus, Generic) Semaglutide is the active ingredient in three Novo Nordisk products authorized for sale in Canada: Ozempic (authorized 2018 for type 2 diabetes, with an expanded indication in 2024 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes), Rybelsus (oral semaglutide tablets authorized for type 2 diabetes), and Wegovy (authorized 2021 for chronic weight management, with an expanded indication in 2024 to reduce the risk of non-fatal myocardial infarction, and a Notice of Compliance with Conditions issued in December 2025 for non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis)
Should be taken with vitamin C to boost glutathione Level
Products may carry risks, including immunogenicity or impurities if mishandled
As the story evolves, there is a change in the use of pronouns from first person singular (me, I) to second person pleural (we, us)
PubMed , International Archives of Occupational and Environmental Health , vol
